Diffuse Large B-cell Lymphoma Associated With Exposure to Agent Orange.

Christopher Tom, Jacob Klickstein, Michelle Chen, Michael Lewis, Michael E Lazarus

Abstract readCase Reports

In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher TomInternal Medicine, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, USA.

Jacob KlicksteinNeurology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, USA.

Michelle ChenInternal Medicine, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, USA.

Michael LewisPathology, Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, USA.

Michael E LazarusInternal Medicine, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Agent Orange (AO) is a toxic herbicide carcinogen mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) that was used extensively during the Vietnam conflict of the 1960s and 1970s. We present a case of an elderly veteran who presented with a progressively enlarging right neck mass. During active combat in Vietnam, he experienced extensive exposure to AO. He was eventually diagnosed with stage I diffuse large B-cell lymphoma (DLBCL) with locally advanced/bulky disease. The patient was deemed higher risk for systemic disease given the skin breakthrough at presentation. Additional labs revealed prior infection with hepatitis B with immunity. There is an association between hepatitis B virus infection and non-Hodgkin lymphoma (NHL). Large epidemiologic studies demonstrate a two times higher risk of developing DLBCL, and it is linked to worse outcomes. He commenced therapy on a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen for six cycles. He was also treated with oral entecavir prophylaxis for 18 months and continued for at least one year after his last rituximab dose.

Indexed as

2 3 7 8-tetrachlorodibenzo-p-dioxin (tcdd)agent orangebcl-2diffuse large b-cell lymphomasub-mandibular mass

Identifiers

PMID42403835

DOI10.7759/cureus.110317

PMCPMC13333179

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.